Teva and Lonza announce discontinuation of Biosimilar joint venture

Have you noticed recent changes to the Biosimilar partnership landscape with established partners deciding to part ways? As Biogeneric manufacturers adjust their development and access strategy based upon updates to the global regulatory landscape, strategic partners can become necessary and also irrelevant in an instant.

In October, the Business of Biosimilars will feature a strategic market overview of the Biosimilar partnerships landscape including trends and recent updates delivered by Giles Somers, Lead Analyst at Data Monitor. Giles heads up the Generics and Biosimilars team, and provides clients with concise strategic insight, as well as new analytical tools such as Biosimilar databases.

After the presentation, Giles will moderate a panel discussion on considerations that must be taken when embarking on a partnership featuring perspectives shared from David Shen at Teva, Carlos Bañado at mAbxience SA as well as others.

Want to learn more? Download our full agenda.

The 14th Annual Business of Biosimilars and Generic Drugs will take place October 15-17, 2012 in Boston, MA. As a reader of this blog, you’ll receive 15% off when you use code XP1886BLOG to register. Have any questions about the event? Feel free to contact Kate Devery at kdevery@iirusa.com or visit the webpage.

Cheers,
The Business of Biosimilars Team

Business of Biosimilars Webpage
Visit our Linkedin
Follow Us On Twitter

Share this article with your social network, just click below to share now!

Share |

[Podcast] Bright future for biomanufacturing

We're excited to announce a new content partnership!  We're teaming up with Datamonitor Healthcare to bring you their latest research and insights into the clinical trials field!

Growth in the biomanufacturing industry is growing at 7% according to a recent podcast with Andrew Badrot, Founder and CEO of CMS Pharma and former Vice President of Strategy at Lonza. Driving this growth in biomanufacturing are things like success in late stage clinical trials, increased production and success with the and new regulations geared at biosimilars. What speaker Badrot also points at is the over-proportional growth that will follow in the manufacturing industry. He predicts that it will grow at more than 9%. However, what traditional companies will see is more competition from emerging markets and more companies due to fewer barriers to entries as a result of single use systems.

Listen to the full podcast here.

If you're interested in finding out more about the current landscape of biomanufacturing, BioProcess International will take place this September and will continue it's look at product and process development and biomanufacturing scientists and executives to share technical, scientific and strategic solutions across all phases of bioprocess development.  For more information on this event, download the agenda.  If you'd like to join us September 16-19 in Boston, as a reader of this blog, when you register to join us and mention code BLOG13JP, you'll save 20% off the standard rate.

Share this article with your social network, just click below to share now!

Share |